Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder
| Status: | Completed |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 40 |
| Updated: | 10/14/2017 |
| Start Date: | September 2010 |
| End Date: | November 2014 |
SSRIs and Self-harm in Borderline Personality Disorder
The goal of this study is to examine the effectiveness the selective serotonin reuptake
inhibitor (SSRI) escitalopram (also known by the trade name "Lexapro") in reducing desire to
self-harm and actual self-harming among young adults with borderline personality disorder who
are also currently depressed. Subjects will receive either escitalopram or placebo for eight
weeks. During this time subjects will be make weekly visits to see the psychiatrist and
record their thoughts and feelings several times each day using an electronic diary.
inhibitor (SSRI) escitalopram (also known by the trade name "Lexapro") in reducing desire to
self-harm and actual self-harming among young adults with borderline personality disorder who
are also currently depressed. Subjects will receive either escitalopram or placebo for eight
weeks. During this time subjects will be make weekly visits to see the psychiatrist and
record their thoughts and feelings several times each day using an electronic diary.
Inclusion Criteria:
- Diagnosis of Borderline Personality Disorder
- Current Major Depression
Exclusion Criteria:
- Past 2 months SSRI use
- Past 6 months non-SSRI antidepressant use
- Past 2 months initiation of psychotherapy
- Lifetime bipolar disorder, organic disorder, psychotic disorder
- Current alcohol or drug dependence
- Current severe suicidal / homicidal ideation necessitating immediate medical
intervention
- Currently pregnancy or nursing
- Unable or unwilling to cooperate with study protocol
We found this trial at
1
site
Click here to add this to my saved trials
